Increasing Bone Sclerosis During Bortezomib Therapy in Multiple Myeloma Patients: Results of a Reduced-Dose Whole-Body MDCT Study

Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

(2011) F. Gay et al.   BLOOD

Successful bone reconstruction after bortezomib therapy in a myeloma patient

(2011) Takayuki Tanaka et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Osteosclerotic lesions in patients treated with gefitinib for lung adenocarcinomas: a sign of favorable therapeutic response

(2011) Yoshiko Yamashita et al.   SKELETAL RADIOLOGY

Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid

(2010) E. Terpos et al.   ANNALS OF ONCOLOGY

Advances in the understanding of myeloma bone disease and tumour growth

(2010) Shmuel Yaccoby   BRITISH JOURNAL OF HAEMATOLOGY

Bone scan images reveal increased osteoblastic function after bortezomib treatment in patients with multiple myeloma

(2010) Sung-Eun Lee et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

(2010) Michele Cavo et al.   LANCET

The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo

(2008) Angela Pennisi et al.   AMERICAN JOURNAL OF HEMATOLOGY

Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma

(2008) C Jakob et al.   LEUKEMIA